Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
Ещё видео!